# Topotecan

## Hycamtin inj 4mg

##### 臨採

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | IHYC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Indications        | Metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. Small cell lung cancer sensitive disease after failure of 1st-line chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | Baseline neutrophil count should be ?1，500/mm3 (1.5 x 10^9/L)， platelets should be ?100，000/mm3 (100 x 10^9/L) and hemoglobin ?9 g/dL prior to treatment; for re-treatment， neutrophil count should be >1，000/mm3 (1 x 10^9/L); platelets >100，000/mm3 and hemoglobin ?9 g/dL. [Ovarian Cancer and Small Cell Lung Cancer] 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days， starting on day 1 of a 21-day course. In the absence of tumor progression， a minimum of 4 courses is recommended because tumor response may be delayed. The median time to response in 3 ovarian clinical trials was 9-12 weeks， and median time to response in 4 small cell lung cancer trials was 5-7 weeks.  [Cervical Cancer] 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1， 2， and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Contraindications  | Severe hypersensitivity to topotecan or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Severe renal impairment (CrCl <20 mL/minute); pregnancy; breastfeeding; severe bone marrow depression                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Neutropenia， leucopenia， thrombocytopenia， anemia， sepsis. GI disturbances， fatigue， fever， pain， asthenia， alopecia， rash， coughing， dyspnea， headache Dermatologic: Alopecia (IV， 49% ; oral， 10% to 20% )， Rash (IV， 16% ) Gastrointestinal: Abdominal pain (5% to 22% )， Constipation (5% to 29% )， Diarrhea (IV， 6% to 32% ; oral， 14% to 22% )， Nausea (IV， 8% to 64% ; oral， 27% to 33% )， Stomatitis (6% to 18% )， Vomiting (IV， 10% to 45% ; oral， 19% to 21% ) Hematologic: Anemia (IV， 89% to 94% ; oral， 94% to 98% )， Leukopenia (IV， 91% to 97% ; oral， 86% to 90% )， Neutropenia (IV， 89% to 97% ; oral， 83% to 91% )， Thrombocytopenia (IV， 69% to 74% ; oral， 81% ) Neurologic: Asthenia (IV， 25% ; oral， 3% to 7% )， Headache (IV， 18% )， Pain (23% ) Respiratory: Cough (15% )， Dyspnea (6% to 22% ) Other: Fatigue (IV， 29% ; oral， 11% to 19% )， Fever (28%， intravenous ; 5% to 7%， oral ) |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data – Potential Toxicity(Mother)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

